Compare
Vonjo vs. Jakafi

Vonjo (pacritinib) is a type of targeted therapy called a JAK inhibitor. It’s used to treat adults with a rare blood cancer called myelofibrosis (MF). This medication specifically helps people with MF who have very low platelet counts. Vonjo (pacritinib) is a capsule that you take by mouth twice a day. The medication might cause side effects like diarrhea, nausea, and swelling. It might also raise the risk of easy bleeding or bruising.

• Intermediate or high-risk primary or secondary myelofibrosis (MF) in adults with a platelet count below 50,000/µL

• Diarrhea (48%)
• Low platelets (34%)
• Nausea (32%)
• Anemia (24%)
• Swelling in the hands, ankles, or feet (20%)
• Vomiting (19%)
• Dizziness (15%)
• Fever (15%)

• Hemorrhage (bleeding)
• Diarrhea
• Low platelet count (thrombocytopenia)
• Changes in heart rhythm
• Risk of serious heart-related or blood-flow problems (e.g., heart attack, stroke)
• Blood clots
• Risk of new cancers
• Higher risk of infection
• Drug interactions

Jakafi (ruxolitinib) is a JAK inhibitor that’s used to treat adults with certain blood conditions called myelofibrosis (MF) and polycythemia vera (PV). This medication is also used to treat graft-versus-host disease (GVHD) in people 12 years and older. Jakafi (ruxolitinib) is a tablet that you take by mouth twice a day. It can cause side effects like low blood cell counts, infection, and tiredness.

• Intermediate or high-risk myelofibrosis (MF) in adults
• Polycythemia vera (PV) in adults who can’t take or have already tried hydroxyurea (Hydrea)
• Acute graft-versus-host disease (aGVHD) in people 12 years and older who’ve already tried corticosteroids
• Chronic graft-versus-host disease (cGVHD) in people 12 years and older who’ve already tried at least one therapy option already

• Infection (e.g., urinary tract infection, viral infection)
• Muscle, bone, or joint pain
• Anemia (low red blood cells)
• Low white blood cells
• Low platelets
• High cholesterol levels
• Higher liver enzyme levels in blood

• Low blood cell counts
• Risk of infection
• Risks when Jakafi (ruxolitinib) is paused or stopped
• Skin cancer
• Possible risk for serious heart problems and stroke
• Possible risk for blood clots
• Possible risk for new cancers